— Know what they know.
Not Investment Advice

THAR NASDAQ

Tharimmune, Inc.
1W: -0.8% 1M: +6.3% 3M: +27.2% YTD: +5.0% 1Y: +208.7% 3Y: -99.0%
$3.54
Last traded 2026-04-22 — delisted
NASDAQ · Healthcare · Biotechnology · $139.9M mcap · 29M float · 2.80% daily turnover · Short 62% of daily vol

Balance Sheet Trends

Total Assets
$519M +13849.5% ▲
5Y CAGR: +345.8%
Total Liabilities
$121M +4921.6% ▲
5Y CAGR: +97.7%
Shareholders Equity
$398M +30330.8% ▲
Cash & Investments
$17M +378.5% ▲
5Y CAGR: +145.3%
Total Debt
$0 +0.0% ▲
Net Debt
-$17M -378.5% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$4K$7M$11M$4M$17M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$4K$7M$11M$4M$17M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$547K$178K$11K$162K$353K
Total Current Assets$622K$7M$11M$4M$17M
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$502M
Total Non-Current Assets$0$0$0$0$502M
Total Assets$622K$7M$11M$4M$519M
— Liabilities —
Accounts Payable$1M$955K$909K$1M$1M
Short-Term Debt$1M$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$980K$0$0$1M$3M
Total Current Liabilities$5M$1M$2M$2M$3M
Long-Term Debt$773K$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$773K$0$0$0$118M
Total Liabilities$5M$1M$2M$2M$121M
— Equity —
Common Stock$636$46$1K$198$4K
Retained Earnings-$7M-$15M-$25M-$37M-$73M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity-$5M$6M$9M$1M$398M
Total Liabilities & Equity$622K$7M$11M$4M$519M
— Key Metrics —
Total Debt$2M$0$0$0$0
Net Debt$2M-$7M-$11M-$4M-$17M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms